This week, we will discuss the largest trial conducted in Alport syndrome. Positive results, but rejected by the FDA. Did they make the right call?
Background
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
Background
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
Background
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
Background
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
